Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported FCF Margin of 595.54% for Q1 2026, down 56687.0% on a YoY basis from N/an in Q1 2025, and down 66.74% quarter-over-quarter from 357.18% in Q4 2025.
Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported FCF Margin for 5 years, with the latest figure at 595.54% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 56687.0% year-over-year to 595.54%; the trailing twelve-month figure through Mar 2026 stood at 111.82% (down 7810.0% YoY), and the FY2025 full-year result was 42.18%, up 1131.0% from the prior year.
- FCF Margin for Q1 2026 stood at 595.54%, down from 357.18% in the prior quarter.
- The five-year high for FCF Margin was 9.93% in Q3 2024, with the low at 25749.32% in Q4 2022.
- Historically, FCF Margin has averaged 2612.64% across 5 years, with a median of 320.31% in 2025.
- The largest YoY upside for FCF Margin was 2471327 bps in 2023 against a maximum downside of 649909 bps in 2023.
- Atara Biotherapeutics' FCF Margin stood at 25749.32% in 2022, then soared by 96 bps to 1036.05% in 2023, then soared by 93 bps to 74.99% in 2024, then tumbled by 376 bps to 357.18% in 2025, then slumped by 67 bps to 595.54% in 2026.
- The last three FCF Margin figures came in at 595.54% (Q1 2026), 357.18% (Q4 2025), and 283.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -595.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -595.54% |
| Dec 31, 2025 | -357.18% |
| Sep 30, 2025 | -283.43% |
| Jun 30, 2025 | -41.64% |
| Mar 31, 2025 | -28.67% |
| Dec 31, 2024 | -74.99% |
| Sep 30, 2024 | -9.93% |
| Jun 30, 2024 | -37.27% |
| Mar 31, 2024 | -108.71% |
| Dec 31, 2023 | -1,036.05% |
| Sep 30, 2023 | -2,397.47% |
| Jun 30, 2023 | -6,621.06% |
| Mar 31, 2023 | -3,167.05% |
| Dec 31, 2022 | -25,749.32% |
| Jun 30, 2022 | -121.96% |
| Mar 31, 2022 | -1,171.96% |